Zacks: Analysts Anticipate Cellular Biomedicine Group Inc (NASDAQ:CBMG) Will Announce Earnings of -$0.78 Per Share

Equities analysts predict that Cellular Biomedicine Group Inc (NASDAQ:CBMG) will post earnings per share of ($0.78) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Cellular Biomedicine Group’s earnings, with the highest EPS estimate coming in at ($0.64) and the lowest estimate coming in at ($0.91). Cellular Biomedicine Group reported earnings of ($0.45) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 73.3%. The firm is scheduled to issue its next earnings results on Tuesday, February 18th.

On average, analysts expect that Cellular Biomedicine Group will report full year earnings of ($2.69) per share for the current financial year, with EPS estimates ranging from ($2.87) to ($2.44). For the next fiscal year, analysts forecast that the company will post earnings of ($2.45) per share, with EPS estimates ranging from ($2.80) to ($1.96). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that follow Cellular Biomedicine Group.

A number of equities research analysts have recently issued reports on the company. BTIG Research assumed coverage on Cellular Biomedicine Group in a report on Tuesday, September 17th. They set a “buy” rating and a $19.00 price objective for the company. BidaskClub upgraded Cellular Biomedicine Group from a “sell” rating to a “hold” rating in a report on Wednesday, October 16th. Finally, ValuEngine upgraded Cellular Biomedicine Group from a “sell” rating to a “hold” rating in a report on Friday. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. Cellular Biomedicine Group presently has a consensus rating of “Buy” and a consensus target price of $24.00.

Shares of CBMG traded down $0.29 during midday trading on Thursday, hitting $17.67. The stock had a trading volume of 69,100 shares, compared to its average volume of 40,408. Cellular Biomedicine Group has a twelve month low of $10.98 and a twelve month high of $20.63. The firm has a market cap of $356.94 million, a price-to-earnings ratio of -8.66 and a beta of 2.93. The company has a 50 day simple moving average of $15.67 and a two-hundred day simple moving average of $14.91.

Several hedge funds have recently modified their holdings of CBMG. Charles Schwab Investment Management Inc. lifted its stake in Cellular Biomedicine Group by 13.2% during the second quarter. Charles Schwab Investment Management Inc. now owns 28,526 shares of the biotechnology company’s stock worth $472,000 after purchasing an additional 3,323 shares during the last quarter. Northern Trust Corp increased its holdings in Cellular Biomedicine Group by 5.0% in the second quarter. Northern Trust Corp now owns 170,273 shares of the biotechnology company’s stock valued at $2,815,000 after purchasing an additional 8,101 shares during the period. Platinum Investment Management Ltd. increased its holdings in Cellular Biomedicine Group by 2.9% in the second quarter. Platinum Investment Management Ltd. now owns 672,885 shares of the biotechnology company’s stock valued at $11,123,000 after purchasing an additional 19,170 shares during the period. Nikko Asset Management Americas Inc. increased its holdings in Cellular Biomedicine Group by 4.8% in the third quarter. Nikko Asset Management Americas Inc. now owns 557,752 shares of the biotechnology company’s stock valued at $8,288,000 after purchasing an additional 25,434 shares during the period. Finally, ARK Investment Management LLC increased its holdings in Cellular Biomedicine Group by 10.0% in the second quarter. ARK Investment Management LLC now owns 314,378 shares of the biotechnology company’s stock valued at $5,197,000 after purchasing an additional 28,616 shares during the period. Institutional investors and hedge funds own 20.49% of the company’s stock.

Cellular Biomedicine Group Company Profile

Cellular Biomedicine Group, Inc, a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer and orthopedic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), a genetically modified T-cell receptors (TCRs), and next generation neoantigen-reactive tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases.

Recommended Story: What is meant by buying and selling pressure?

Get a free copy of the Zacks research report on Cellular Biomedicine Group (CBMG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cellular Biomedicine Group (NASDAQ:CBMG)

Receive News & Ratings for Cellular Biomedicine Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group and related companies with MarketBeat.com's FREE daily email newsletter.